Crestline Management LP Purchases Shares of 8,272 BioNTech SE (NASDAQ:BNTX)

Crestline Management LP acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 8,272 shares of the company’s stock, valued at approximately $943,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its position in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. boosted its holdings in shares of BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE bought a new stake in BioNTech during the 4th quarter worth approximately $90,000. GAMMA Investing LLC increased its holdings in BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new position in BioNTech in the 4th quarter valued at $137,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Trading Down 2.1 %

BNTX opened at $92.77 on Friday. The firm’s fifty day moving average is $98.79 and its two-hundred day moving average is $109.51. The firm has a market cap of $22.26 billion, a PE ratio of -44.18 and a beta of 1.35. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same period in the previous year, the company posted $1.90 earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on BNTX shares. Truist Financial initiated coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. BMO Capital Markets increased their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Morgan Stanley dropped their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday. Finally, Citigroup reissued a “buy” rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus target price of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.